semaglutide naion risk is associated with an increased risk of NAION - NAIONGLP-1 semaglutide users Understanding the Semaglutide NAION Risk: What the Latest Research Reveals

NAIONtirzepatide The emergence of semaglutide as a potent medication for managing type 2 diabetes and obesity has brought with it significant therapeutic advancements. However, as with any medication, understanding potential risks is paramount for both healthcare providers and patients.Should You Stop Taking GLP-1 Drugs Like Ozempic if ... A growing body of research is focusing on a specific concern: the semaglutide NAION risk, referring to nonarteritic anterior ischemic optic neuropathySemaglutide Use Increases NAION Risk in Patients With .... This article delves into what current studies indicate about this potential association, exploring the nuances of the increased NAION risk and providing a comprehensive overview based on the latest scientific findings.

What is NAION?

Nonarteritic anterior ischemic optic neuropathy (NAION) is a serious eye condition that occurs when blood flow to the optic nerve is disrupted, leading to damage and vision loss. It is a leading cause of acquired optic neuropathy in developed countries《眼科衛教-2》 前幾天「瘦瘦針恐致眼中風失明」的 .... While the exact mechanisms are not fully understood, risk factors can include vascular disease, diabetes, hypertension, and certain medications.

The Link Between Semaglutide and NAION: Emerging Evidence

Several studies have investigated whether the use of semaglutide is associated with an increased risk of NAION. While the findings are not entirely uniform, a trend suggests a potential association, particularly in certain patient groups.

* Cohort Studies and Increased Risk: Large-scale cohort studies have provided significant data糖尿病、過重與肥胖者使用Semaglutide上升非動脈炎前缺血 .... For instance, one study involving 16,827 patients revealed a higher risk of NAION in patients prescribed semaglutide compared to those on non-glucagon-based medications. Another comprehensive Danish cohort study of 424,152 persons with type 2 diabetes found that use of once-weekly semaglutide independently more than doubled the risk of NAION over a five-year period.Ozempic and other weight-loss drugs linked to sudden ... This doubling of risk has been a recurring finding, indicating a measurable increase for semaglutide users.

* Specific Patient Populations: The semaglutide NAION risk appears to be more pronounced in certain subgroups.Specifically, in the diabetes group, 17 out of 200 patients onsemaglutidedevelopedNAION, a rate four times higher than those not on the medication. In the ... Studies indicate a particularly elevated risk among individuals with type 2 diabetes. In some analyses, semaglutide users vs non-users was significantly increased in people with type 2 diabetes, with hazard ratios as high as 42025年6月6日—If patients experience a sudden loss of vision or rapidly worsening eyesight during treatment withsemaglutide, they should contact their doctor ....28 noted. Furthermore, for individuals treated for obesity, the risk appeared more than seven times higher. This suggests that pre-existing conditions like diabetes and obesity might influence susceptibility to this side effect. Research also points to a 3Semaglutide and NAION.31 times higher risk of NAION in semaglutide recipients aged 40 to 64 compared to the same age group not on the medication.

* Duration of Exposure and Predisposing Factors: Semaglutide use shows association with increased NAION risk, particularly with prolonged exposure and in patients with predisposing factors.16小时前—Among people with diabetes, those takingsemaglutidewere around four times more likely to be diagnosed withNAIONthan similar patients not using the drug. Among people treated for obesity, theriskappeared more than seven times higher. The absoluteriskremains low, but in certain ... This highlights the importance of considering the duration of treatment when evaluating potential ocular complications.

Understanding the Magnitude of the Risk

Despite the identified association, it's crucial to contextualize the actual magnitude of this risk. Multiple sources emphasize that NAION is a very rare side effect of semaglutide. Estimates suggest it may potentially affect up to 1 in 10,000 users作者：NJ ABBASS·2025·被引用次数：30—The cumulative 5-yearriskofNAIONand ION in T2DM patients on semaglu- tide was 0.065% and 0.08%, respectively. In those with high BMI prescribedsemaglutide, .... The European Medicines Agency (EMA) has also reviewed the data, concluding that NAION is a very rare adverse event. The overall risk for NAION remains low, even among those on semaglutide. The excess absolute risk is low, meaning that while the relative risk might increase, the number of individuals experiencing this severe outcome remains small.

* Cumulative Risk Data: Cumulative five-year risks of NAION in patients on semaglutide have been reported as approximately 0.065%.Semaglutide, type 2 diabetes, and the risk of nonarteritic ... This figure further underscores the rarity of the condition.

What About Other GLP-1 Receptor Agonists?

The research extends to other medications within the GLP-1 receptor agonist class. Findings indicate that exenatide, another GLP-1 receptor agonist, has also been associated with an increased risk of NAION, suggesting this might be a class effect rather than specific to semaglutide alone. Investigations into the effect of semaglutide and GLP-1 RAs on risk of NAION are ongoingNAION from GLP-1 Drugs: What Colorado Patients Should Know.

Navigating the Risk: Expert Opinions and Recommendations

Healthcare professionals and regulatory bodies are actively monitoring and researching the semaglutide NAION risk.

* European Medicines Agency (EMA) Review: The EMA's review concluded that NAION is a very rare side effect of semaglutide.Specifically, in the diabetes group, 17 out of 200 patients onsemaglutidedevelopedNAION, a rate four times higher than those not on the medication. In the ... They have also provided guidance that the use of semaglutide for managing type 2 diabetes has been associated with an increased risk of NAION when compared with the use of SGLT-2 inhibitors.

* Clinical Recommendations: If patients experience a sudden loss of vision or rapidly worsening eyesight during treatment with semaglutide, they should contact their doctor immediately. This proactive approach is vital given the irreversible nature of NAION.Semaglutide Linked to Nonarteritic Anterior Ischemic Optic ... While some studies suggest that semaglutide may not be associated with an increased risk of NAION in the general population, prudent clinical practice involves continued vigilance.

* Ongoing Research: Upcoming studies are recommended to aim to identify high-risk subgroups and further elucidate the mechanisms behind this potential association. The ongoing analysis of semaglutide and nonarteritic anterior ischemic optic neuropathy aims to provide more definitive answers2024年8月6日—The risk of NAION insemaglutide users vs non-users was significantly increasedin people with type 2 diabetes (HR=4.28; 95% CI: 1.62, 11.29 ....

Conclusion

The semaglutide NAION risk is a recognized area of research, with a growing body of evidence suggesting an association between semaglutide use and an increased risk of developing NAION, particularly in patients with type 2 diabetes and obesity, and with prolonged use.Use of semaglutide and risk of non-arteritic anterior ... However, it is critical to reiterate that NAION is a very rare side effect of semaglutide, and the overall risks associated with untreated diabetes and obesity often outweigh this potential ocular complication.Once-weekly semaglutide doubles the five-year risk of ... Patients considering or currently taking semaglutide should engage in open discussions with their healthcare providers about their individual risk factors and potential benefits. Continued research is essential to refine our understanding and ensure the safe and effective use of this important medication.PRAC concludes eye condition NAION is a very rare side ...